20051209
 Schering AG: Option Is Reviewed to Protect Betaseron From Generic Rivalry   The Wall Street Journal,  Dec 10, 2005  German drug maker Schering AG said Friday it is considering exercising an option that analysts say could cost it $1 billion but would give it the chance to fend off generic competition to its best- selling multiple-sclerosis drug, Betaseron.   
